Emyria to Benefit from Final TGA Ruling on CBD Medicines
Filed with ASX · · 3 pages · English
● Final decision from Australia’s Therapeutic Goods Administration (TGA) confirms requirement for product-specific safety and efficacy data to support registrationof low-dose CBD products (<150mg/day) as Schedule 3 medicines for all proposed doses and indications ● Emyria Data is one of the largest clinical-trial-grade data sets covering safety and efficacy data on over 3,000 patients for a wide range
Earlier from Emyria
- Emyria Sees Strong Interest in IBS Study
- Emyria Launches Drug Development Program Based on RWE
- Emyria Partners with Thought Leaders in Psychedelic Therapy
- Emyria Enters Data Deal with ZLD to Support Autism Trial
- Webinar on Global Partnership with Sapphire Medical Clinics
Later from Emyria
- Emyria Pursuing Registration of EMD-003 in CY2021
- FDA Position on RWE to Guide Registration
- Emyria wins digital health monitoring grant with UWA
- Emyria adds second Emerald Clinic in Melbourne
- Emyria Adds Second Clinical Site in Perth
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria